Pneumologie 2020; 74(S 01): 100-101
DOI: 10.1055/s-0039-3403290
Posterbegehung (PO20) – Sektion Klinische Pneumologie
Fortschritte bei Lungenfibrosen 2020
Georg Thieme Verlag KG Stuttgart · New York

Association between weight loss and decline in FVC in patients with IPF*

U Costabel
1   Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Germany
,
B Crestani
2   Hôpital Bichat, Pneumologie, Paris, France
,
V Cottin
3   National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France
,
R Thibault
4   Numecan Institute, Inra, Inserm, Univ Rennes, Nutrition Unit, Chu Rennes, Rennes, France
,
M Lederlin
5   Department of Radiology, Pontchaillou Hospital, Rennes 1 University, Rennes, France
,
L Vernhet
6   Univ Rennes, Chu Rennes, Inserm, Ehesp, Irset (Institut de Recherche En Santé, Environnement et Travail), Rennes, France
,
W Stansen
7   Boehringer Ingelheim GmbH & Co. Kg, Ingelheim am Rhein, Germany
,
M Quaresma
8   Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
,
S Jouneau
9   Hôpital Pontchaillou – Chu de Rennes, Irset Umr 1085, Université de Rennes 1, Rennes, France
› Author Affiliations
Further Information

Publication History

Publication Date:
28 February 2020 (online)

Also available at
 
 

    Introduction: Weight loss has been associated with worse survival in patients with idiopathic pulmonary fibrosis (IPF).

    Aim: To assess the association between weight loss and disease progression measured as decline in forced vital capacity (FVC) in patients with IPF in the INPULSIS trials.

    Methods: In post-hoc analyses, we assessed the rate of decline in FVC (mL/yr) over 52 weeks in subgroups by weight loss from baseline over 52 weeks (weight gain/no weight loss; 0 to ≤ 5% weight loss; > 5 to ≤ 10% weight loss; > 10% weight loss) using random coefficient regression.

    Results: Among 421 patients in the placebo group, the proportions with no, 0 to ≤ 5%, > 5 to ≤ 10% and > 10% weight loss over 52 weeks were 45.6%, 34.7%, 13.1% and 6.7%, respectively. At baseline, subgroups with greater weight loss over 52 weeks had a higher mean age, lower proportion of males, lower mean DLco % predicted and lower mean FVC % predicted. In the placebo group, the mean rate of decline in FVC over 52 weeks increased with increasing weight loss ([Fig. 1]). In contrast, similar rates of decline in FVC were observed in nintedanib-treated patients (n = 635) irrespective of weight loss.

    Zoom Image
    Fig. 1 Rate of decline in FVC (mL/yr) over 52 weeks in the INPULSIS trials in subgroups by weight loss over 52 weeks.

    Conclusion: In the INPULSIS trials, patients with greater weight loss showed faster disease progression when treated with placebo, and a more pronounced treatment effect of nintedanib.

    * presented at ERS 2019, ‡ presenting on behalf of the authors


    #
     
    Zoom Image
    Fig. 1 Rate of decline in FVC (mL/yr) over 52 weeks in the INPULSIS trials in subgroups by weight loss over 52 weeks.